Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-19 · Built: 2026-10-19 · 中文

← United States · Coverage record

US · SEC FORM 4

MediWound Ltd.

MDWD · Nasdaq · CIK 0001593984 · Healthcare · Biotechnology

INSIDER SIGNAL

55.6 / 100

3 buyers · 7 purchase transaction lines · $142.7K gross purchase

WHY THIS SIGNAL?

Buyer breadthModerate
Purchase sizeLow
RoleStrong
RecencyLow
ConvictionLow
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+21.0 / 35
Purchase size+5.9 / 25
Role+20.0 / 20
Recency+4.5 / 10
Conviction+4.2 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 3 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Buying conviction is reduced by concurrent selling
  • ✓ Role scores high · most senior buyer: Director

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Purchase breadth & concentration

QUALIFYING BUYERS3
PURCHASE CONCENTRATION59%Largest buyer: SHAMIR NACHUM · $84.0K
CLUSTER BUYING · 15D3 insidersPeak activity: 2026-05-29–2026-06-03

Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Rubinstein SamuelDirector
●●▼
Hess ShmuelCOO & Chief Commercial Officer
▼▼
SHAMIR NACHUMDirector
●
Fox David MortonDirector
●
● Purchase▼ Sale○ Other

—

SIGNAL HISTORY

55.6 / 100

Latest recorded score

↓ -0.1 ptsversus the previous recorded snapshot
  1. 56.2
  2. 56.0
  3. 55.9
  4. 55.7
  5. 55.6

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

7Purchases
4Sales
0Other Form 4 lines
5SEC filings · 365 days
BUYING7 qualifying P line(s) · 180 days
SELLING4 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-8.5%
3M
-12.0%
6M
-29.7%
12M
-28.9%

Volatility & liquidity

Volatility
44.4%
Beta
—
Avg daily value
USD 1.1M

Valuation

Market cap
—
P/E
—

Fundamentals

Profit margin
—
ROE
—
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
1,844,691
Previous report
1,813,385
Avg daily volume
65,380
Days to cover
28.2

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-01Rubinstein SamuelPurchase (P)Ordinary Shares525USD 12.62USD 6,626SEC filing ↗
2026-06-03SHAMIR NACHUMPurchase (P)Ordinary Shares6,000USD 14.00USD 83,996SEC filing ↗
2026-06-01Fox David MortonPurchase (P)Ordinary Shares3,537USD 14.11USD 49,918SEC filing ↗
2026-05-29Rubinstein SamuelPurchase (P)Ordinary Shares150USD 14.33USD 2,150SEC filing ↗

Form 4 evidence

11 transaction lines in the latest 365-day window; 11 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-01Rubinstein SamuelSale (S)Ordinary Shares525USD 12.72USD 6,678SEC filing ↗
2026-09-01Rubinstein SamuelPurchase (P)Ordinary Shares525USD 12.62USD 6,626SEC filing ↗
2026-08-27Hess ShmuelSale (S)Ordinary Shares3,958USD 12.93USD 51,157SEC filing ↗
Show recent Form 4 evidence (7 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-01Rubinstein SamuelSale (S)Ordinary Shares525USD 12.72USD 6,678SEC filing ↗
2026-09-01Rubinstein SamuelPurchase (P)Ordinary Shares525USD 12.62USD 6,626SEC filing ↗
2026-08-27Hess ShmuelSale (S)Ordinary Shares3,958USD 12.93USD 51,157SEC filing ↗
2026-08-26Hess ShmuelSale (S)Ordinary Shares1,865USD 13.00USD 24,245SEC filing ↗
2026-06-03SHAMIR NACHUMPurchase (P)Ordinary Shares6,000USD 14.00USD 83,996SEC filing ↗
2026-06-01Fox David MortonPurchase (P)Ordinary Shares3,537USD 14.11USD 49,918SEC filing ↗
2026-05-29Rubinstein SamuelPurchase (P)Ordinary Shares150USD 14.33USD 2,150SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-19
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerMDWD
CIK0001593984
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2833 Medicinal Chemicals & Botanical Products
ExchangeNasdaq

Data coverage

Local Form 4 history11 transaction lines from 2026-05-29 to 2026-09-01
7 P purchase lines · 4 S sale lines · 0 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.